A meta-analysis suggests allogeneic stem cell transplantation (allo-SCT) should not be recommended following first-line ...

The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.

Defining "value" in cancer care goes beyond survival and should encompass patient quality of life metrics, said Coral Omene, MD, PhD, of Robert Wood Johnson Medical School.